Objectives: Classify the species of Candida that cause vulvovaginal candidiasis and establish their patterns of antifungal susceptibility. Style of the Study: This was a cross-sectional study. Location and Period of Study: The study was performed between December 2012 and February 2013 at the Mbarara Regional Referral Hospital prenatal clinic in Mbarara Municipality. Methods: High vaginal swabs were performed by microscopy and culture on Sabouraud Dextrose Agar in 456 pregnant women. The germ tube and Analytical profile index (API ® Candida) analyses established Candida isolates. Susceptibility to fluconazole, itraconazole and voriconazole was determined by the Etest strips and by the disc diffusion method for clotrimazole and nystatin on Mueller Hinton agar with 2 percent w / v glucose and 0.5μg / ml methylene blue dye supplementation. Results: Of the 456 cultivated High Vaginal Swabs, 207 Candida species developed. The distribution of the species was as follows: C. The Albicans (78.95%), C. (14.35 percent) glabrata, C. The Krusei (3.35%), C. Tropicalis (percentage 1.44), C. Famata (0.96%), C. (0.48 percent) of parapsilosis and C. Lusitaniae (0.48%). Nystatin resistance has been found in just 0.61 percent of C. Albicans. Albicans. Clotrimazole resistance was observed at 50 percent, 36.67 percent and 0.61 percent of C. Oh, Famata, C. C. and glabrata. Albicans. Albicans. C. Krusei demonstrated a high resistance to fluconazole of 71.43 percent. C. It’s Glabrata, C. Krusae, C. C. and Famata. Lusitaniae was 100% itraconazole resistant. Only C demonstrated resistance to voriconazole of less than 11 percent. C. and Albicans. Glabrata a glabrata Finding: C. Albicans, except for itraconazole and voriconazole, were susceptible to most of the antifungal agents studied. All isolates, except less than 1 percent of Candida albicans, were susceptible to nystatin. Resistance to certain drugs , especially itraconazole, was shown by Nonalbicans. For empirical management of vulvovaginal candidiasis in pregnant women, we suggest the use of Nystatin.
Author (s) Details
Kiguli James Mukasa
Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.
Itabangi Herbert
Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda
Dr. Atwine Daniel
Department of Clinical Research, Epicentre Mbarara Research Centre, Mbarara, Uganda and Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda.
Kibuka Livingstone Sserunkuma
Department of Microbiology, Makerere College of Health Sciences, Makerere University, Kampala, Uganda.
Bazira Joel
Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.
Byarugaba Frederick
Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.
View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/278